$Eli Lilly(LLY)$ is experiencing a notable correction today, driven by disappointing Q4 sales guidance. The company's expected sales of $13.5B fell short of consensus estimates ($14B), with underwhelming performances from Zepbound (obesity) and Mounjaro (diabetes).

I've learned to recalibrate my perspective on such events. Rather than succumbing to fear, I recognize opportunities to buy the dip as a prudent long-term strategy.

Notably, LLY serves as a strategic diversification component in my portfolio, providing a relatively stable hedge against the volatility inherent in my technology and cryptocurrency holdings. This allocation helps balance risk and potential returns, underscoring the importance of thoughtful portfolio construction.